Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor.
Activation of the androgen receptor (AR) is induced by ligand binding through conformational changes leading to control of gene expression. Antiandrogens compete with androgens for AR occupancy and subsequently block at least one step in AR action. Analysis of nuclear transfer kinetics using the GFP-AR fusion protein and partial proteolysis analysis provided evidence that the ligand-bound receptor was in equilibrium between at least two distinct conformations, leading to the production of 35 and 29 kDa trypsin-resistant fragments. It also indicated that this equilibrium may regulate the rate of nuclear transfer. The slowing of nuclear transfer by antiandrogens was correlated with the amount of receptor in conformation leading to the 35 kDa trypsin-resistant fragment. To establish the role of heat shock protein (hsp) 90 activity in antiandrogenic action, the effect of geldanamycin (GA) was evaluated in both in vitro assays and live cells. We demonstrated that in vitro hsp90s are required to stabilize the receptor in the inactive conformation and that hsp90 activity is involved in the integrity and nuclear transfer of agonist- and antagonist-bound AR. Furthermore, nuclear transfer is not the only step affected by GA since this compound was also active on a constitutively nuclear AR (GFP-NLS-AR). Hsp90 inactivation impedes interaction of androgen-bound GFP-NLS-AR with nuclear components and inhibits transcriptional activity. We conclude that hsp90s are required for the acquisition of active conformation in agonist-bound AR to regulate nuclear transfer, nuclear matrix binding, and transcriptional activity. Pure antiandrogens block the transconformational change of AR in an intermediary complex unable to acquire the active conformation and to dissociate the hsp90.
Georget
Virginie
V
Pathologie Moléculaire des Récepteurs Nucléaires, Institut National de la Santé et de la Recherche Médicale, INSERM U439, 70 Rue de Navacelles, 34090 Montpellier, France.
Térouanne
Béatrice
B
Nicolas
Jean-Claude
JC
Sultan
Charles
C
D021581:Active Transport, Cell Nucleus / Q000187:drug effects / Q000235:genetics; D000726:Androgen Antagonists / Q000737:chemistry* / Q000494:pharmacology*; D000818:Animals; D016227:Benzoquinones; D019556:COS Cells; D002460:Cell Line; D002467:Cell Nucleus / Q000737:chemistry / Q000187:drug effects / Q000235:genetics; D010450:Endopeptidases; D049452:Green Fluorescent Proteins; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D006801:Humans; D006868:Hydrolysis; D007700:Kinetics; D047029:Lactams, Macrocyclic; D008164:Luminescent Proteins / Q000235:genetics; D008856:Microscopy, Fluorescence; D010957:Plasmids; D011487:Protein Conformation; D011809:Quinones / Q000494:pharmacology; D011944:Receptors, Androgen / Q000737:chemistry* / Q000235:genetics / Q000502:physiology*; D015534:Trans-Activators / Q000737:chemistry* / Q000235:genetics / Q000502:physiology*; D014162:Transfection
D000726:Androgen Antagonists; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D008164:Luminescent Proteins; D011809:Quinones; D011944:Receptors, Androgen; D015534:Trans-Activators; D049452:Green Fluorescent Proteins; D010450:Endopeptidases; C001277:geldanamycin